Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study.


Journal

Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278

Informations de publication

Date de publication:
12 2021
Historique:
revised: 01 10 2021
received: 21 05 2021
accepted: 06 10 2021
pubmed: 19 11 2021
medline: 15 3 2022
entrez: 18 11 2021
Statut: ppublish

Résumé

To evaluate changes over 3 years in the thickness of inner retinal layers including the peripapillary retinal nerve fiber layer (pRNFL), and combined macular ganglion cell and inner plexiform layers (mGCIPL), in individuals with relapsing-remitting multiple sclerosis (RRMS) versus healthy controls; to determine whether optical coherence tomography (OCT) is sufficiently sensitive and reproducible to detect small degrees of neuroaxonal loss over time that correlate with changes in brain volume and disability progression as measured by the Expanded Disability Status Scale (EDSS). Individuals with RRMS from 28 centers (n = 333) were matched with 64 healthy participants. OCT scans were performed on Heidelberg Spectralis machines (at baseline; 1 month; 6 months; 6-monthly thereafter). OCT measurements were highly reproducible between baseline and 1 month (intraclass correlation coefficient >0.98). Significant inner retinal layer thinning was observed in individuals with multiple sclerosis (MS) compared with controls regardless of previous MS-associated optic neuritis--group differences (95% CI) over 3 years: pRNFL: -1.86 (-2.54, -1.17) µm; mGCIPL: -2.03 (-2.78, -1.28) µm (both p < 0.0001; effect sizes 0.39 and 0.34). Greater inner retinal layer atrophy was observed in individuals diagnosed with RRMS <3 years versus >5 years (pRNFL: p < 0.05; mGCIPL: p < 0.01). Brain volume decreased by 1.3% in individuals with MS over 3 years compared to 0.5% in control subjects (effect size 0.76). mGCIPL atrophy correlated with brain atrophy (p < 0.0001). There was no correlation of OCT data with disability progression. OCT has potential to estimate rates of neurodegeneration in the retina and brain. The effect size for OCT, smaller than for magnetic resonance imaging based on Heidelberg Spectralis data acquired in this study, was increased in early disease.

Identifiants

pubmed: 34792863
doi: 10.1002/acn3.51473
pmc: PMC8670323
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2235-2251

Subventions

Organisme : Novartis Pharma

Informations de copyright

© 2021 Novartis Pharma AG. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Références

Ann Neurol. 2015 Nov;78(5):801-13
pubmed: 26190464
PLoS One. 2012;7(4):e34823
pubmed: 22536333
J Neurol. 2016 Jul;263(7):1323-31
pubmed: 27142714
Ann Neurol. 2019 May;85(5):618-629
pubmed: 30851125
Ann Neurol. 2005 Dec;58(6):840-6
pubmed: 16283615
Neurol Neuroimmunol Neuroinflamm. 2018 Mar 13;5(3):e449
pubmed: 29552598
Expert Rev Neurother. 2019 Jan;19(1):31-43
pubmed: 30587061
Mult Scler. 2009 Sep;15(9):1092-102
pubmed: 19556315
Neurology. 2007 Oct 16;69(16):1603-9
pubmed: 17938370
Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2520-7
pubmed: 10509645
Lancet Neurol. 2017 Oct;16(10):797-812
pubmed: 28920886
Brain. 2002 Oct;125(Pt 10):2202-12
pubmed: 12244078
J Neurol Sci. 2014 Sep 15;344(1-2):88-93
pubmed: 25005893
Clin Ophthalmol. 2010 Sep 20;4:1007-13
pubmed: 20922034
Br J Ophthalmol. 2010 Jul;94(7):871-6
pubmed: 19822916
Mult Scler. 2015 Feb;21(2):163-70
pubmed: 24948688
Nat Rev Neurol. 2018 Feb;14(2):75-93
pubmed: 29326424
Ann Neurol. 2015 Feb;77(2):228-36
pubmed: 25382184
Lancet Neurol. 2010 Sep;9(9):921-32
pubmed: 20723847
Mult Scler. 2017 Apr;23(5):721-733
pubmed: 28206827
Neurology. 2019 Feb 5;92(6):e527-e535
pubmed: 30674600
ISRN Ophthalmol. 2012 Jul 30;2012:860819
pubmed: 24558593
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Nat Rev Neurol. 2010 Mar;6(3):125-6
pubmed: 20212426
Eur J Neurol. 2020 Nov;27(11):2225-2232
pubmed: 32602573
BMC Neurol. 2018 May 11;18(1):67
pubmed: 29751782
PLoS One. 2011 Apr 08;6(4):e18132
pubmed: 21494659
Nat Rev Neurol. 2020 Mar;16(3):171-182
pubmed: 32094485
J Neurol. 2008 Oct;255(10):1555-60
pubmed: 18825432
JAMA Neurol. 2013 Jan;70(1):34-43
pubmed: 23318513
Mult Scler. 2012 Jun;18(6):891-8
pubmed: 22190573
Lancet Neurol. 2016 May;15(6):574-84
pubmed: 27011339
Neurology. 2013 Jan 1;80(1):47-54
pubmed: 23267030
Ann Neurol. 2010 Jun;67(6):749-60
pubmed: 20517936
Lancet Neurol. 2012 Nov;11(11):963-72
pubmed: 23041237
Eur Neurol. 2020;83(5):508-516
pubmed: 32957101
Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1213-1223
pubmed: 30913293
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Invest Ophthalmol Vis Sci. 2012 Mar 09;53(3):1251-7
pubmed: 22266522
Front Neurol. 2020 Jun 17;11:450
pubmed: 32625158
Mult Scler. 2011 Dec;17(12):1449-63
pubmed: 21865411
Neurol Sci. 2020 Nov;41(11):3175-3183
pubmed: 32356126
Rev Neurol (Paris). 2010 Dec;166(12):978-86
pubmed: 20605617
Clin Neurol Neurosurg. 2010 Oct;112(8):647-52
pubmed: 20452719
Neurology. 2016 Jun 14;86(24):2303-9
pubmed: 27225223
JAMA Neurol. 2013 May;70(5):629-33
pubmed: 23529376
Neurol Neuroimmunol Neuroinflamm. 2017 Dec 15;5(1):e427
pubmed: 29259999

Auteurs

Friedemann Paul (F)

NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Berlin, Germany.

Peter A Calabresi (PA)

Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland, USA.

Frederik Barkhof (F)

Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands.
Institutes of Neurology & Centre for Medical Image Computing, University College London, London, UK.

Ari J Green (AJ)

Department of Neurology, Multiple Sclerosis Center, University of California San Francisco, San Francisco, Califonia, USA.

Randy Kardon (R)

Iowa City VA Center for Prevention and Treatment of Visual Loss, Department of Veterans Affairs Hospital Iowa City, University of Iowa Hospital and Clinics, Iowa City, Iowa, USA.
Department of Ophthalmology and Visual Sciences, University of Iowa Hospital and Clinics, Iowa City, Iowa, USA.

Jaume Sastre-Garriga (J)

Department of Neurology/Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

Sven Schippling (S)

Neuroimmunology and Multiple Sclerosis Research Section, University Hospital Zurich, Zurich, Switzerland.

Patrick Vermersch (P)

Univ. Lille, Inserm UMR1172 LilNCog, FHU Precise, Lille, France.

Shiv Saidha (S)

Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.

Bianca S Gerendas (BS)

Department of Ophthalmology, Vienna Reading Center, Medical University of Vienna, Vienna, Austria.

Ursula Schmidt-Erfurth (U)

Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.

Catherine Agoropoulou (C)

Novartis Pharma AG, Basel, Switzerland.

Ying Zhang (Y)

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

Gustavo Seifer (G)

Novartis Pharma AG, Basel, Switzerland.

Axel Petzold (A)

Moorfields Eye Hospital, The National Hospital for Neurology and Neurosurgery, London, UK.
Queen Square Institute of Neurology, University College London, London, UK.
MS Center Amsterdam, Amsterdam UMC (Locatie VUmc), Amsterdam, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH